Escherichia Coli Infections - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 148 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Escherichia Coli Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Escherichia Coli Infections - Pipeline Review, H2 2014', provides an overview of the Escherichia Coli Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Escherichia Coli Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Escherichia Coli Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Escherichia Coli Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Escherichia Coli Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Escherichia Coli Infections Overview 8
Therapeutics Development 9
Pipeline Products for Escherichia Coli Infections - Overview 9
Pipeline Products for Escherichia Coli Infections - Comparative Analysis 10
Escherichia Coli Infections - Therapeutics under Development by Companies 11
Escherichia Coli Infections - Therapeutics under Investigation by Universities/Institutes 14
Escherichia Coli Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Escherichia Coli Infections - Products under Development by Companies 18
Escherichia Coli Infections - Products under Investigation by Universities/Institutes 21
Escherichia Coli Infections - Companies Involved in Therapeutics Development 22
Adenium Biotech ApS 22
Arsanis Biosciences GmbH 23
AvidBiotics Corp. 24
Bellus Health Inc. 25
Bioorganic Research and Services S.A. 26
Cellceutix Corporation 27
Chiesi Farmaceutici SpA 28
ConjuGon, Inc. 29
Debiopharm International S.A. 30
Evolva SA 31
GangaGen Inc. 32
Genentech, Inc. 33
GlycoVaxyn AG 34
Immuron Limited 35
Melinta Therapeutics, Inc 36
Northern Antibiotics Oy 37
Nosopharm SAS 38
NovaBay Pharmaceuticals, Inc. 39
Novabiotics Ltd 40
Nymox Pharmaceutical Corporation 41
Pherecydes Pharma SA 42
Phico Therapeutics Ltd. 43
Procarta Biosystems Ltd 44
Sanofi Pasteur SA 45
Sealife PHARMA GMBH 46
Sequoia Sciences, Inc. 47
Soligenix, Inc. 48
Spider Biotech 49
Syntiron LLC 50
Trana Discovery, Inc. 51
Escherichia Coli Infections - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
A-3APO - Drug Profile 61
AA-139 - Drug Profile 63
ACE-920 - Drug Profile 65
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 66
BNT-006 - Drug Profile 67
Debio-1454 - Drug Profile 68
Drugs for Bacterial Infections - Drug Profile 69
enterotoxigenic escherichia coli conjugate Vaccine - Drug Profile 70
Escherichia coli (whole cell) vaccine - Drug Profile 71
Escherichia coli vaccine - Drug Profile 72
ETEC Adhesin-Based Vaccine - Drug Profile 73
ETEC Vaccine - Drug Profile 74
EV-009 - Drug Profile 75
EV-021 - Drug Profile 76
EV-035 - Drug Profile 77
extraintestinal pathogenic escherichia coli vaccine - Drug Profile 79
GN-4474 - Drug Profile 80
IMM-363 - Drug Profile 81
INX-201 - Drug Profile 82
MDN-0057 - Drug Profile 83
MDN-0058 - Drug Profile 85
MDN-0059 - Drug Profile 87
MDN-0060 - Drug Profile 89
Monoclonal Antibodies for Escherichia Coli Infections - Drug Profile 91
NAB-7061 - Drug Profile 92
NAB-739 - Drug Profile 94
NAB-741 - Drug Profile 95
NOSO-95 - Drug Profile 97
NP-432 - Drug Profile 98
NVC-727 - Drug Profile 99
NXC-4720 - Drug Profile 100
Oligonucleotide for Gram Negative Infections - Drug Profile 101
Peptides for Oncology and Infectious Disease - Drug Profile 102
PMX-1278 - Drug Profile 103
PMX-1363 - Drug Profile 104
PMX-1405 - Drug Profile 105
PMX-247 - Drug Profile 106
PP-0121 - Drug Profile 107
Proteins for Infectious Diseases - Drug Profile 109
PT-4 - Drug Profile 110
Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections - Drug Profile 111
RX-04 - Drug Profile 112
RX-05 - Drug Profile 113
RXP-873 - Drug Profile 114
SB-041 - Drug Profile 115
SGX-942 - Drug Profile 116
Shigamabs - Drug Profile 118
Shigetec - Drug Profile 120
SLP-0901 - Drug Profile 121
SLP-0905 - Drug Profile 122
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 123
Small Molecule to Inhibit Rns and VirF for Bacterial Infections - Drug Profile 124
Small Molecules for Bacterial Infections - Drug Profile 125
Small Molecules for Bacterial Infections - Drug Profile 126
Small Molecules for Bacterial Infections - Drug Profile 127
Small Molecules for Escherichia Coli Infections - Drug Profile 128
Small Molecules to Inhibit 30S RNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile 129
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 130
uropathogenic escherichia coli vaccine - Drug Profile 131
Escherichia Coli Infections - Recent Pipeline Updates 132
Escherichia Coli Infections - Dormant Projects 139
Escherichia Coli Infections - Discontinued Products 140
Escherichia Coli Infections - Product Development Milestones 141
Featured News & Press Releases 141
Appendix 143
Methodology 143
Coverage 143
Secondary Research 143
Primary Research 143
Expert Panel Validation 143
Contact Us 144
Disclaimer 144

List of Tables
Number of Products under Development for Escherichia Coli Infections, H2 2014 13
Number of Products under Development for Escherichia Coli Infections - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 16
Number of Products under Investigation by Universities/Institutes, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Development by Companies, H2 2014 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2014 25
Escherichia Coli Infections - Pipeline by Adenium Biotech ApS, H2 2014 26
Escherichia Coli Infections - Pipeline by Arsanis Biosciences GmbH, H2 2014 27
Escherichia Coli Infections - Pipeline by AvidBiotics Corp., H2 2014 28
Escherichia Coli Infections - Pipeline by Bellus Health Inc., H2 2014 29
Escherichia Coli Infections - Pipeline by Bioorganic Research and Services S.A., H2 2014 30
Escherichia Coli Infections - Pipeline by Cellceutix Corporation, H2 2014 31
Escherichia Coli Infections - Pipeline by Chiesi Farmaceutici SpA, H2 2014 32
Escherichia Coli Infections - Pipeline by ConjuGon, Inc., H2 2014 33
Escherichia Coli Infections - Pipeline by Debiopharm International S.A., H2 2014 34
Escherichia Coli Infections - Pipeline by Evolva SA, H2 2014 35
Escherichia Coli Infections - Pipeline by GangaGen Inc., H2 2014 36
Escherichia Coli Infections - Pipeline by Genentech, Inc., H2 2014 37
Escherichia Coli Infections - Pipeline by GlycoVaxyn AG, H2 2014 38
Escherichia Coli Infections - Pipeline by Immuron Limited, H2 2014 39
Escherichia Coli Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 40
Escherichia Coli Infections - Pipeline by Northern Antibiotics Oy, H2 2014 41
Escherichia Coli Infections - Pipeline by Nosopharm SAS, H2 2014 42
Escherichia Coli Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2014 43
Escherichia Coli Infections - Pipeline by Novabiotics Ltd, H2 2014 44
Escherichia Coli Infections - Pipeline by Nymox Pharmaceutical Corporation, H2 2014 45
Escherichia Coli Infections - Pipeline by Pherecydes Pharma SA, H2 2014 46
Escherichia Coli Infections - Pipeline by Phico Therapeutics Ltd., H2 2014 47
Escherichia Coli Infections - Pipeline by Procarta Biosystems Ltd, H2 2014 48
Escherichia Coli Infections - Pipeline by Sanofi Pasteur SA, H2 2014 49
Escherichia Coli Infections - Pipeline by Sealife PHARMA GMBH, H2 2014 50
Escherichia Coli Infections - Pipeline by Sequoia Sciences, Inc., H2 2014 51
Escherichia Coli Infections - Pipeline by Soligenix, Inc., H2 2014 52
Escherichia Coli Infections - Pipeline by Spider Biotech, H2 2014 53
Escherichia Coli Infections - Pipeline by Syntiron LLC, H2 2014 54
Escherichia Coli Infections - Pipeline by Trana Discovery, Inc., H2 2014 55
Assessment by Monotherapy Products, H2 2014 56
Number of Products by Stage and Target, H2 2014 58
Number of Products by Stage and Mechanism of Action, H2 2014 60
Number of Products by Stage and Route of Administration, H2 2014 62
Number of Products by Stage and Molecule Type, H2 2014 64
Escherichia Coli Infections Therapeutics - Recent Pipeline Updates, H2 2014 136
Escherichia Coli Infections - Dormant Projects, H2 2014 143
Escherichia Coli Infections - Discontinued Products, H2 2014 144